We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00356889
Recruitment Status : Completed
First Posted : July 27, 2006
Results First Posted : May 20, 2013
Last Update Posted : May 28, 2014
Information provided by (Responsible Party):

Study Description
Brief Summary:
This phase II trial is studying how well giving bevacizumab together with erlotinib hydrochloride works in treating patients with metastatic or unresectable biliary tumors. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and erlotinib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving bevacizumab together with erlotinib hydrochloride may kill more tumor cells.

Condition or disease Intervention/treatment Phase
Cholangiocarcinoma of the Extrahepatic Bile Duct Cholangiocarcinoma of the Gallbladder Gastrointestinal Cancer Recurrent Extrahepatic Bile Duct Cancer Recurrent Gallbladder Cancer Unresectable Extrahepatic Bile Duct Cancer Unresectable Gallbladder Cancer Drug: erlotinib hydrochloride Biological: bevacizumab Phase 2

Detailed Description:


I. Evaluate the objective response rate in patients with metastatic or unresectable cholangiocarcinoma treated with bevacizumab and erlotinib hydrochloride.


I. Evaluate time to progression in these patients.

II. Evaluate overall and progression-free survival of these patients.

III. Evaluate the adverse events associated with this regimen. OUTLINE: This is an open-label, multicenter study.

Patients receive bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.

After completion of study therapy, patients are followed periodically for up to 3 years.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Bevacizumab and Erlotinib in Patients With Advanced Biliary Tumors
Study Start Date : May 2006
Primary Completion Date : October 2008
Study Completion Date : June 2010

Arms and Interventions

Arm Intervention/treatment
Experimental: Bevacizumab and Erlotinib Hydrochloride

Patients receive 5 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15 and 150 mg oral erlotinib hydrochloride daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.

Tumor tissue and blood specimens are collected periodically for correlative studies. Specimens are examined by immunohistochemistry for epidermal growth factor receptor (EGFR) and P-EGFR protein levels; AKT p-AKT, mitogen-activated protein kinase (MAPK) and P-MAPK protein levels; and vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2 protein levels. EGFR mutations are detected by laser capture microdissection. Enzyme-linked immunosorbent assay is used to measure total and free serum VEGF levels.

Drug: erlotinib hydrochloride
Given orally, 150 mg, once daily.
Other Names:
  • CP-358,774
  • erlotinib
  • OSI-774
Biological: bevacizumab
Given IV, 5mg/kg on days 1 and 15 every cycle
Other Names:
  • anti-VEGF humanized monoclonal antibody
  • anti-VEGF monoclonal antibody
  • Avastin
  • rhuMAb VEGF

Outcome Measures

Primary Outcome Measures :
  1. Number of Confirmed Tumor Responses. [ Time Frame: After 6 courses of treatment. Each course lasts 28 days. ]

    Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the target lesions.

    A confirmed tumor response is defined to be either a Complete Response or a Partial Response noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Confirmed tumor responses will be evaluated using the first 6 cycles of treatment. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment and had one post-baseline disease assessment will be evaluable for response. Forty-nine of the 53 eligible patients had at least one post-baseline disease assessment and were evaluable for this endpoint.

Secondary Outcome Measures :
  1. Survival Time [ Time Frame: From registration to death due to any cause, assessed up to 3 years ]
    Estimated using the method of Kaplan-Meier (1958).

  2. Time to Disease Progression [ Time Frame: From registration to documentation of disease progression, assessed up to 3 years ]
    Estimated using the method of Kaplan-Meier (1958).

  3. Duration of Response [ Time Frame: From the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented, assessed up to 3 years ]
    Point estimates and 95% confidence intervals were calculated using the method of Duffy and Santner (1987).

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Absolute neutrophil count >= 1,500/mm3
  • Histologically or cytologically confirmed cholangiocarcinoma or gallbladder carcinoma:

    • Metastatic or surgically unresectable disease
  • Measurable disease, defined as >= 1 lesion whose longest diameter can be accurately measured as >= 2.0 cm with conventional techniques or as > 1.0 cm with spiral CT scan:

    • Spiral CT scan imaging must be used for pre- and post-treatment tumor measurements of lesions measuring >= 1.0 cm to < 2.0 cm
  • Clinical lesions will only be considered measurable when they are superficial

    • Lesions on chest x-ray are acceptable as measurable lesions when they are clearly defined and surrounded by aerated lung
  • No ampulla of Vater tumors
  • No evidence of CNS disease
  • Life expectancy >= 3 months
  • ECOG performance status 0-2
  • Platelet count >= 75,000/mm3
  • Total bilirubin =< 2 times ULN
  • ALT and AST =< 2.5 times ULN
  • Creatinine =< 2 mg/dL
  • Albumin >= 2.5 g/dL
  • Alkaline phosphatase =< 5 times ULN
  • Urine protein:creatinine ratio < 1.0 OR 24-hour urine protein < 1000 mg
  • No concurrent illness or medical condition, including any of the following:

    • Impairment of gastrointestinal (GI) function or disease that may significantly alter the absorption of erlotinib hydrochloride
    • Requirement for IV alimentation
  • No concurrent illness or medical condition, including any of the following:

    • Active peptic ulcer disease;
    • Serious or nonhealing wound, ulcer, or bone fracture;
    • GI bleed that required procedural intervention within the past 3 months
  • No concurrent illness or medical condition, including any of the following:

    • Abdominal fistula, GI perforation, or intra-abdominal abscess within the past 28 days
    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Psychiatric illness or social situation that would limit study compliance
  • No other malignancy within the past 3 years
  • No abnormalities of the cornea
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No clinically significant cardiovascular disease
  • More than 4 weeks since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered
  • No significant traumatic injury within the past 28 days
  • No prior systemic anticancer therapy for metastatic gallbladder or bile duct cancer
  • More than 28 days since prior major surgery [Note: Insertion of a vascular access device is not considered major/minor surgery]
  • More than 2 weeks since prior minor surgery [Note: Insertion of a vascular access device is not considered major/minor surgery]
  • More than 7 days since prior core biopsy
  • No concurrent major surgery
  • No other concurrent chemotherapy, immunotherapy, radiotherapy, or any other therapy or supportive care considered investigational
  • No concurrent enzyme-inducing antiepileptic drugs or any other CYP3A4 inducer, such as rifampin or Hypericum perforatum
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No other concurrent investigational agents or other concurrent anticancer therapies
  • No concurrent prophylactic hematopoietic colony-stimulating factors
  • Concurrent full-dose anticoagulants allowed provided PT/INR is > 1.5 and both of the following criteria are met:

    • In-range INR on a stable dose of oral anticoagulant OR on a stable dose of low molecular weight heparin
  • AND (continued from above) No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels, gastrointestinal ulcerations, or known varices)
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00356889

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: William Schelman Mayo Clinic
More Information

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00356889     History of Changes
Obsolete Identifiers: NCT01646957, NCT01664416
Other Study ID Numbers: NCI-2009-00115
CDR0000484566 ( Registry Identifier: PDQ (Physician Data Query) )
N01CM17104 ( U.S. NIH Grant/Contract )
First Posted: July 27, 2006    Key Record Dates
Results First Posted: May 20, 2013
Last Update Posted: May 28, 2014
Last Verified: April 2013

Additional relevant MeSH terms:
Gallbladder Neoplasms
Gastrointestinal Neoplasms
Bile Duct Neoplasms
Biliary Tract Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Biliary Tract Diseases
Digestive System Diseases
Gallbladder Diseases
Gastrointestinal Diseases
Bile Duct Diseases
Erlotinib Hydrochloride
Antibodies, Monoclonal
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Immunologic Factors
Protein Kinase Inhibitors